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Background: Impaired skeletal muscle regeneration could contribute to the progression of muscle atrophy in
patients with chronic obstructive pulmonary disease (COPD).
Methods: Satellite cells and myogenesis-related proteins were compared between healthy subjects and patients
with COPD, with or without muscle atrophy. Satellite cells were isolated and cultured to assess their proliferative
and differentiation aptitudes.
Results: Although satellite cell numbers in muscle samples were similar between groups, the proportion of muscle
fibers with central nuclei was increased in COPD. In muscle homogenates, increased expression of MyoD and
decreased expression of myogenin and MRF4 were observed in COPD. In cultured satellite cells of patients with
COPD, increased protein content was observed for Pax7, Myf5 (proliferation phase) and myogenin (differentiation
phase) while myosin heavy chain protein content was significantly lower during differentiation.
Conclusion: In COPD, the number of central nuclei was increased in muscle fibers suggesting a greater number of
attempts to regenerate muscle tissue than in healthy subjects. Myogenesis signaling was also altered in muscle
homogenates in patients with COPD and there was a profound reduction in the differentiation potential in this
population as indicated by a reduced ability to incorporate myosin heavy chain into newly formed myotubes.
Collectively, these results indicate that skeletal muscle regenerative capacity termination is impaired in COPD and
could contribute to the progression of muscle atrophy progression in this population.
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Skeletal muscle atrophy is observed in a variety of acute
and chronic conditions [1-5] including chronic obstruct-
ive pulmonary disease (COPD) [6]. In COPD, this loss of
muscle mass has a significant impact on quality of life
[7] and is associated with premature death [8]. Many
biochemical factors have been proposed to initiate and
promote the development of skeletal muscle atrophy in
COPD [9]. An impaired capacity for muscle regeneration
has been hypothesized to take part in this process [10].
However, no studies have yet investigated whether the
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unless otherwise stated.could be involved in the atrophying process in the con-
text of COPD.
Skeletal muscle possesses a remarkable capacity to re-
generate itself, which largely depends on muscle satellite
cells and the expression of myogenic regulatory factors
(MRFs). Upon activation [11-13], satellite cells prolifer-
ate into myoblasts and migrate to the requested site. In
the activated state, these cells will enter the cell cycle
through the expression of early MRFs such as MyoD
and Myf5 [14]. Eventually, newly formed myoblasts will
exit the cell cycle and differentiate into myotubes. At
this stage cells will express two distinct MRFs, myogenin
and MRF4. Fully differentiated myotubes will fuse to in-
jured myofibers for repair or fuse together to form a
new one [15]. To preserve an adequate population ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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myoblasts will return to a quiescent state [16,17].
Transition of activated satellite cells to highly prolifera-
tive myoblasts and then to differentiated myotubes is a
well regulated process. First, up-regulation of Notch sig-
naling promotes the transition of activated satellite cells to
highly proliferative myoblasts [18]. A subsequent decline
in Notch signaling activity is necessary for differentiation
of progenitor cells into fusion competent myoblasts [19].
Increases in the expression of Numb is known to switch
off Notch signaling [18]. The transition from Notch to
Wnt signaling in myogenic progenitors is a prerequisite
step for differentiation [20].
Muscle is highly dynamic and muscle mass mainten-
ance relies on the delicate balance between protein syn-
thesis and degradation as well as the additions and loss
of myonuclei. We hypothesized that the regenerative
process is impaired in COPD patients presenting muscle
atrophy compared to healthy individuals. This hypoth-
esis is supported by our recent finding that satellite cell
senescence is likely occurring in lower limb muscle of
patients with COPD and low muscle mass [21]. To fur-
ther test this hypothesis, the research protocol was
divided in two distinct aims: 1) in muscle tissue, to
evaluate satellite cell number, by counting the occur-
rence of central nuclei (a marker of newly fused satellite
cells) and to study the expression pattern of myogenesis-
related proteins; and 2) in isolated and cultured satellite
cells, to assess proliferation, MRFs expression and differ-
entiation as key steps of the regeneration process. This
study confirms that although limb muscle of patients
with COPD and healthy age matched controls contains
the same number of satellite cells, their myogenic cap-
acities are impaired in COPD.
Methods
Subjects
Seventeen males with Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) stage III and IV disease
and nine healthy male subjects with normal lung func-
tion were consecutively recruited for this study. None of
them were part of a previous study on satellite cell biol-
ogy in COPD21. COPD diagnosis was based on a past
smoking history (> 10 pack-year) and pulmonary func-
tion tests showing persistent airflow obstruction (forced
expiratory volume in 1 s [FEV1] < 50% of predicted value
and FEV1/forced vital capacity [FVC] < 70%) [22]. All pa-
tients with COPD were in a stable condition at the time
of the study and were neither suffering from any other
diseases nor using oral corticosteroids. The institutional
ethics committee (Comité d’éthique, Institut Universitaire
de cardiologie et de pneumologie de Québec) approved
the study protocol and each patient signed a written
informed consent form.Study design
To address aim #1, muscle sections and homogenates of
all study participants were used respectively for immuno-
staining and protein measurements. Eight patients with
COPD and seven healthy subjects had sufficient amount
of muscle tissue for isolation and culture of satellite cells
and fulfilled the second aim of this study.
Pulmonary function, anthropometric measurements and
body composition
Standard pulmonary function tests including spirometry,
lung volumes, and carbon dioxide diffusion capacity
were obtained in all subjects during the initial evaluation
according to previously described guidelines [23]. Results
were related to previously published normal values [24].
Height and weight were measured according to standard-
ized methods [1]. Mid-thigh muscle cross-sectional area
(MTCSA) was determined using computed tomography,
as previously described [8].
Muscle biopsy
One needle biopsy of the vastus lateralis, performed as
described by Bergström and routinely done in our labora-
tory, [25] was obtained from each participant. Muscle
specimens were divided in two parts. One was frozen in li-
quid nitrogen and stored at −80°C for analyses on immu-
nostained muscle sections and on muscle homogenates
(aim #1)). When sufficient tissue was available, the second
part of the muscle specimen (COPD n = 8; controls n = 7)
was placed in a sterile plate filled with phosphate-buffered
saline (PBS), covered and transported on ice under ster-
ile cell culture hood to perform satellite cell isolation
(aim #2).
Fiber typing
Muscle sections were stained with a monoclonal anti-
myosin (skeletal, fast) antibody (Sigma-Aldrich, St-Louis,
MO, USA) to detect type II muscle fibers using a stand-
ard immunohistochemistry protocol. The proportion of
type I (nonstained), and II (darkly stained) fibers was
assessed and calculated as the number of fibers of each
type divided by the total number of muscle fibers on the
cryosection.
Satellite cells and myonuclei staining
To assess the number of satellite cells in muscle tissue sec-
tions, immunostaining against transcription factor Pax7
(R&D Systems) was performed. Laminin was used to de-
lineate muscle fibers. Nuclei were labeled using DAPI. Nu-
clei located deep to the basal lamina and positive for Pax7
were counted as satellite cells. Satellite cells were counted
in over 100 myofibers and reported as a ratio. Muscle sec-
tions (10 μm) were fixed with ice-cold acetone and metha-
nol 60/40 (v/v) at – 20°C for 20 minutes, washed with
Thériault et al. Respiratory Research 2014, 15:35 Page 3 of 11
http://respiratory-research.com/content/15/1/35PBS, incubated with a blocking solution (horse serum 1%)
for 1 hour and then incubated with the primary antibody
overnight at 4°C in a humidified chamber. The primary
antibody Pax-7 (R&D Systems) and laminin (Dako,
Glostrup, Denmark) excess was cleaned with PBS, in-
cubated with their specific secondary antibodies, a goat
anti-mouse Alexa Fluor® 488 (R&D Systems) and a goat
anti-rabbit Alexa Fluor® 546 (Invitrogen Corporation,
Carlsbad, CA, USA) for 1 hour, washed with PBS and
then incubated with DAPI for 15 minutes. Slides were
analyzed and images were captured using a Nikon
Eclipse E600 microscope (Nikon Corporation, Tokyo,
Japan). Immunofluorescences were performed in duplicate
on two different muscle cryosections.Satellite cell isolation and culture
Satellite cells were isolated and cultured as previously
published [26]. Briefly, fresh muscle samples were placed
in a sterile plate filled with phosphate-buffered saline
(PBS), covered and transported on ice under sterile cell
culture hood. All subsequent manipulations were per-
formed under sterile conditions. Muscle samples were
minced into a slurry using a scalpel and subjected to enzym-
atic digestion for 1 h with 0,33% collagenase (Cedarlane,
Hornby, ON, Canada) at 37˚C with gentle agitation. The
digested muscle specimens were then dissociated by trit-
urating them several times and filtered through a 100 μm
filter (BD Biosciences, Franklin Lakes, NJ, USA). Cells
were plated and grown on collagen coated dishes (Sigma-
Aldrich) in growth medium made of Dulbecco’s modified
Eagle’s medium (DMEM) with 1% glucose (HyClone,
Logan, UT, USA) supplemented with 20% fetal bovine
serum, penicillin 50 U/ml, streptomycin 50 μg/ml
(HyClone) and 5 ng/ml bFGF (Promega, Madison, WI,
USA) in a humidified 37°C, 5% CO2 incubator. The
medium was changed every two days and the cultures
examined by inverted-phase microscopy. When cul-
tured cells reached a confluence of 70% they were disso-
ciated enzymatically with trypsin (Gibco, Carlsbad, CA,
USA) and seeded for immediate propagation, or frozen
into medium containing 10% DMSO for later use. To
induce differentiation into myotubes, near to confluence
myoblasts were placed in differentiation medium made
of DMEM with 1% glucose and supplemented with 2%
horse serum (HS), penicillin 50 U/ml, and streptomycin
50 μg/ml (HyClone). Differentiation medium was re-
placed every day for 7 consecutive days. Images taken
from myoblasts and myotubes were captured with a
Nikon 950 digital camera (Nikon Corporation). To en-
sure the exclusivity of the myogenic nature of the cell
culture, Pax-7 (R&D Systems, Minneapolis, NE, USA)
staining was performed. Immunohistochemistry was
performed using Vectastain Elite ABC Kit according tothe instructions provided by the manufacturer (Vector
Labs, Burlingame, CA, USA).
Proliferation assay
After the first passage, satellite cells were plated at a
density of 5 × 104 cells in a 60 mm cultures dish. Every
24 h, cells were trypsinized and counted using a hemacy-
tometer during four successive days.
MRFs expression
To measure progression through myogenesis, 2 × 105 cells
were placed in a 100 mm dish after their second passage.
Cells were allowed 24 hours to settle and adhere before
starting the experiment. Near confluent myoblasts were
placed in differentiation medium for seven consecutive
days. Whole cell lysates were performed every 24 h until
complete differentiation for a total of nine days in culture.
Western blotting against Pax7 (R&D), MyoD, Myf5, Myo-
genin, MRF4 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and Numb (Cell Signaling Technology, Danvers,
MA, USA) was performed to quantify myogenesis related
protein accumulation.
Differentiation assay
To measure differentiation rate, 2 × 105 cells were placed
in a 60 mm dish after their second passage. Near conflu-
ent myoblasts were placed in differentiation medium for
seven consecutive days. Cell lysates were prepared every
24 h until seven days of differentiation. To quantify dif-
ferentiation, western blotting against monoclonal anti-
myosin (skeletal, fast) antibody (Sigma-Aldrich) was
performed.
Statistical analysis
Results are expressed as mean (± SEM). Data from pa-
tients with COPD and healthy controls were analyzed
using a one-way analysis of variance (ANOVA). Because
low muscle mass is related to poor quality of life [27],
reduced functional capacity [7] and survival [8], immu-
nostaining and tissue homogenate data obtained from
patients with COPD were subsequently subdivided ac-
cording to a MTCSA <70 cm2 or >70 cm2 for further
sub-analysis purposes. The 70 cm2 MTCSA threshold
was used to define muscle atrophy based on a previous
study showing that mortality was significantly increased
in patients with MTCSA below this cutoff value [8]. Dif-
ferences for all variables between patients with COPD
with MTCSA <70 cm2 and >70 cm2 and healthy controls
were analyzed using a one-way analysis of variance
(ANOVA). Muscle mass was not considered in the ana-
lysis of cultured satellite cell data because the compos-
ition of the study groups was based on amount of tissue
available for cell isolation and not on baseline subject
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Anthropometric characteristics and pulmonary function
data are provided in Table 1. Patients with COPD with
MTCSA > 70 cm2 and healthy subjects did not signifi-
cantly differ in age and body mass index. Patient with
COPD and MTCSA < 70 cm2 had a significantly lower
body mass index compared to the other two groups. On
average, patients with COPD had moderate-to-severe
airflow obstruction: eight patients had stage III COPD
and nine patients had stage IV disease according to the
GOLD classification [28]. Type I fiber proportion was
significantly decreased in patients with COPD, while
type II fiber proportion was reciprocally increased.
Satellite cells and central nuclei quantification
A representative vastus lateralis cryosection immuno-
stained for Pax7 (expressed by satellite cells) and laminin
(a major constituent of the basal lamina) is depicted in
Figure 1A. The proportion of myofibers positive for Pax7
did not significantly differ between groups (Figure 1B).
A representative cryosection immunostained for nucleus
and laminin is provided in Figure 2A. The number ofTable 1 Subject characteristics
Characteristics Control
(n = 9)
COPD > 70 cm2
(n = 11)
COPD < 70 cm2
(n = 6)
Age (years) 63 ± 2.3 64 ± 2.3 70 ± 2.4
BMI (kg/m2) 29.1 ± 2.4 28.1 ± 2.0 21.7 ± 2.6b
FEV1, L 3.3 ± 0.2 1.0 ± 0.2
a 0.8 ± 0.1a
FEV1, % predicted 106.3 ± 4.1 36.0 ± 4.9
a 26.0 ± 3.8a
FEV1/FVC, % 76.0 ± 1.6 36.1 ± 1.8
a 29.0 ± 2.6b
TLC, % predicted 98.6 ± 6.5 121.6 ± 6.6a 125.7 ± 4.8a
RV, % predicted 90.1 ± 15.3 173.2 ± 22.8a 195.5 ± 22.9a
DLCO, % predicted 96.9 ± 3.2 57.4 ± 6.7
a 40.0 ± 2.8b
MTCSA (cm2) 120.3 ± 3.4 86.3 ± 4.2a 60.8 ± 3.6b
Type I fiber
Distribution, % 51.5 ± 5.7 34.7 ± 9.3a 34.9 ± 3.5a
CSA, (μm2) 5170 ± 471 4711 ± 340 4883 ± 607
Type II fiber
Distribution, % 44.1 ± 5.7 65.4 ± 9.3a 65.2 ± 3.5a
CSA, (μm2) 4216 ± 358 4359 ± 540 4096 ± 480
Values are means ± SEM.
astatistically significant difference from control (p < 0.05).
bstatistically significant difference from COPD > 70 cm2 (p < 0.05).
Definition of abbreviations: BMI Body mass index, FEV1 Forced expiratory
volume in 1 second, TLC total lung capacity, RV Residual volume, DLCO
Diffusing capacity of carbon monoxide, MTCSA Mid-thigh cross-sectional area,
CSA Cross-sectional area.central nuclei (a marker of newly fused satellite cells) per
100 muscle fibers was significantly higher in patients with
COPD and preserved muscle mass (MTCSA > 70 cm2)
compared to patients with COPD and muscle atrophy
(MTCSA < 70 cm2) and healthy subjects (7.2 ± 0.7 vs
3.2 ± 0.2 vs 4.0 ± 0.5 respectively; p < 0.0001) (Figure 2B).
Expression of myogenic regulatory factors
A significant increase in MyoD protein content was ob-
served in patients with COPD with MTCSA < 70 cm2
(Figure 3) compared to healthy subjects (2.31 fold-
increase, p < 0.05) and to patients with COPD with
MTCSA > 70 cm2 (1.31 fold-increase, p < 0.05). Myf5 pro-
tein content was significantly increased in both groups of
patients with COPD compared to healthy subjects (1.42
and 1.49 fold-increase respectively, p < 0.05). There was
a significant decrease in myogenin (0.62 fold-decrease,
p < 0.005) and MRF4 (0.46 fold-decrease, p < 0.005) protein
contents in patients with COPD with MTCSA> 70 cm2
compared to healthy subjects. There was no difference
between Pax7 and Numb (total amount) protein content
between all three groups.
Satellite cell analyses
To further characterize satellite cells present in the vastus
lateralis biopsies, a protocol to isolate and culture muscle
satellite cells was developed. Proliferation and differentiation
rates of the satellite cells were determined using this model.
Subject’s characteristics
Anthropometric characteristics and pulmonary function
data for subjects in whom primary muscle cell culture
was performed are provided in Table 2.
Isolation and characterization of satellite cells
Cultured cells demonstrated myoblast-like and myotubes-
like shapes in growing and differentiation states. Positive
staining for Pax7 confirmed the satellite cell phenotype of
these cells. In all cultures, at least 95% of freshly isolated
muscle progenitor cells were classified as Pax7+ satellite
cells by immunohistochemistry. Cells were grown under
sterile conditions and no signs of any contamination were
observed.
When satellite cells were isolated from the muscle
samples and put into culture, a delay in their adhesion
into dishes was observed. Satellite cells isolated from pa-
tients with COPD took 7.3 ± 0.3 days to adhere and pro-
liferate compared to 5.5 ± 0.3 days (p < 0.05) for those
isolated from healthy subjects.
Proliferation
Cell proliferation was evaluated by counting growing
cells every 24 hours over a 96-hour period. The number
of cells at each time point is presented in Figure 4. A
Figure 1 Satellite cell detection performed by immunostaining. (A) Vastus lateralis muscle cryosections were immunostained for
co-expression and localization of nuclear Paired box transcription factor 7 (Pax7, green), DAPI (blue) and laminin (red). Labeled nuclei located deep
to the basal lamina and positive for pax7 were counted as satellite cells (white arrow). (B) Labeled nuclei located deep to the basal lamina and
positive for Pax7 were counted as satellite cells. The number of satellite cells is expressed over 100 fibers and reported as a ratio; ANOVA; p > 0.05.
Ratios are calculated from 9 healthy subjects, 11 COPD (MTCSA > 70 cm2) and 6 COPD (MTCSA < 70 cm2).
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ation was observed at 48 hours in patients with COPD
compared to healthy subjects (p < 0.01). At 72 hour, pro-
liferation rate in COPD was similar compared to healthy
subjects with even a significant increase in proliferation
at 96 hours in COPD compared to healthy individuals
(p < 0.005).
Myogenesis
Cells were grown in proliferation medium for two days
than placed in differentiation medium for the remaining
period of time. In COPD, there was a significant increase
in Pax7 accumulation after one day in growing culture
medium compared to healthy subjects (2.0 fold-increase,
p < 0.05) (Figure 5A). MyoD protein accumulation dur-
ing this period was similar between groups while signi-
ficant increases in Myf5 protein accumulation (p < 0.05)Figure 2 Central nuclei detection performed by immunostaining. (A)
laminin (red). Immuno-detection is shown for 10 μm skeletal muscle cryose
100 fibers and reported as a ratio. Ratios are calculated from 9 healthy sub
(B) Nucleus inside the perimeter of a given fiber delimited by laminin wa
reported as a ratio. When a is present: statistically significant difference fr
from COPD > 70 cm2 (ANOVA; p < 0.05).were observed in COPD compared to healthy subjects in
our distinct days during differentiation (days 4 (3.2 fold-
increase), 5 (3.6 fold-increase), 7 (2.9 fold-increase) and 9
(3.5 fold-increase) (p < 0.05)) (Figure 5B and C, respect-
ively). Significant increases in the accumulation of myo-
genin in patients with COPD compared to healthy subjects
were observed at days 0 (2.2 fold-increase) and 1 during
proliferation (1.7 fold-increase) (p < 0.05) (Figure 5D).
The accumulation of MRF4 did not differ between
groups (Figure 5E). Significant decreases in the accumula-
tion of Numb in patients with COPD compared to healthy
subjects were observed throughout the proliferation and
differentiation periods (Figure 5F).
Differentiation
At the end of the myogenic process, the capacity of myo-
blasts to fully differentiate into myotubes was determinedCryosections were analyzed by immunostaining for nuclei (blue) and
ctions. The number of central nuclei (white arrows) is expressed over
jects, 11 COPD (MTCSA > 70 cm2) and 6 COPD (MTCSA < 70 cm2).
s counted as a central nucleus, expressed over 100 fibers and
om control. When b is present b: statistically significant difference
Figure 3 Western blot against Pax7 (A), MyoD (B), Myf5 (C), Myogenin (D), MRF4 (E) and Numb (F) total protein extract of the muscle
biopsies obtained from the vastus lateralis. Results are reported as a percentage compared to controls subjects. When a is present: statistically
significant difference from control. When b is present b: statistically significant difference from COPD > 70 cm2 (ANOVA; p < 0.05).
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seven days (Figure 6). After three days of differentiation,
there was a profound decrease in the accumulation of
MHC in COPD compared to healthy subjects that per-
sisted throughout the rest of the differentiation period.
Discussion
One of the most striking consequences of COPD is the
reduction in lower limb muscle mass resulting in loss of
muscle strength [29,30] which has a significant impact
on exercise tolerance [31], quality of life [7] and survival
[8]. In the present study we sought to determine the
contribution of satellite cell activity in the development
of limb muscle atrophy in patients with COPD. Our first
assessments were performed directly on muscle speci-
mens using histological characterisation and proteincontent measurements. Even though the number of satel-
lite cells was similar in all groups of subjects tested, indi-
cation of increased regenerative events as evidenced by
the increased number of central nuclei, was found in pa-
tients with COPD and preserved muscle mass compared
to patients with COPD and low muscle mass and healthy
subjects. Because satellite cells activation, proliferation
and differentiation are strongly regulated by the cell envir-
onment, we developed primary cell cultures derived from
muscle biopsies to further investigate satellite cells intrin-
sic capacity during proliferation and differentiation. It was
found that satellite cells from patients with COPD have a
delay in activation that was followed by a significant re-
duction in MHC accumulation at the end of the myogenic
process demonstrating a defect during myotube matur-
ation. Overall, these results are in agreement with a
Table 2 Subjects characteristics used for primary culture
Characteristics Control (n = 7) COPD (n = 8)
Age 63 ± 2.3 66 ± 2.3
BMI (kg/m2) 29.1 ± 2.4 28.8 ± 2.0
FEV1, L 3.3 ± 0.2 1.0 ± 0.1
a
FEV1, % predicted 106.3 ± 4.1 37.0 ± 4.0
a
FEV1/FVC, % 76 ± 1.6 36.5 ± 1.1
a
TLC, % predicted 98.6 ± 6.5 118.0 ± 5.5
RV, % predicted 90.1 ± 15.3 163.5 ± 15.9a
DLCO, % predicted 96.9 ± 3.2 53.3 ± 5.8
a
MTCSA (cm2) 120.3 ± 3.4 82.3 ± 6.5a
Satellite cells (Pax7+/100 fibers) 2.6 ± 0.4 1.7 ± 0.3a
Central nuclei (count/100 fibers) 4.0 ± 0.8 6.5 ± 1.0a
Values are means ± SEM.
astatistically significant difference from control (p < 0.05).
Definition of abbreviations: BMI Body mass index, FEV1 Forced expiratory
volume in 1 second, TLC total lung capacity, RV Residual volume,
DLCO Diffusing capacity of carbon monoxide, MTCSA Mid-thigh
cross-sectional area.
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compromise the regenerative potential in lower limb
muscles of patients with COPD.
Myogenic characteristics of the vastus lateralis
Satellite cell number
In order to sustain an appropriate regenerative function
and thus be able to support muscle fiber repair, satellite
cell population must remain constant during lifespan. In
accordance, the density of satellite cells was similar in the
three groups of subjects that were investigated. We and
others reported similar results in patients with COPD with
or without muscle atrophy [21,32]. Together, these resultsFigure 4 Proliferative potential in satellite cells isolated and
cultured from healthy subjects (white bars) and patients with
COPD (black bars). Following the first passage, 5 × 104 cells were
seeded on a 60 mm-dish and were counted every next 24 hours
during 96 consecutive hours. Values are expressed as mean ± SEM.
When a is present: statistically significant difference from control
(ANOVA; p < 0.05).demonstrate that satellite cell number is maintained in pa-
tients with COPD and suggests that chronic lung disease
does not have a significant impact on the rate of decline of
the satellite cell population [32].
Central nuclei and regenerative events
Upon activation, satellite cells multiply and commit their
development into myoblasts [12]. The capacity of myo-
blasts to differentiate into myotubes and form new myo-
fibers is the last critical step for muscle regeneration
[12]. The number of central myonuclei is an indication
of committed satellite cells into the repair process
[15,33,34]. Surprisingly we found a higher ratio of cen-
tral nuclei in patients with COPD without muscle atro-
phy when compared to patients with COPD and muscle
atrophy and healthy subjects, which suggest an increase
in the number of regenerative events in this particular
group. This observation demonstrates that satellite cells
can be activated in this population and also supports the
hypothesis that muscle tissue might be more exposed to
injury during the progression of the disease [35-37]. On
the other hand, in patients with a MTCSA < 70 cm2, a
decrease in the occurrence of regenerative events com-
pared to patients with COPD and preserved muscle
mass is seen, confirming a previous finding by our group
[21]. This observation could be interpreted as an ex-
haustion of the regenerative potential because of satellite
cell senescence [21].
MRFs protein levels
Myogenesis is mainly controlled by four myogenic regu-
latory factors: MyoD, Myf5, Myogenin and MRF4 which
are successively activated upon the initial transcriptional
activity of Pax7 by the Notch signaling pathway [38].
MyoD is expressed in muscle satellite cells and mature
myofibers [12]. We observed an upregulation of MyoD
and Myf5 protein contents in whole muscle extracts
from patients with COPD and muscle atrophy suggest-
ing an attempt to accentuate proliferation. These results
are in contrast to the study of Plant et al. who did not
find any difference in the level of expression of MyoD in
whole muscle protein lysates between patients with
COPD and healthy subjects [39]. In the group of pa-
tients with COPD and preserved muscle mass, the in-
creased expression of Myf5 (proliferation), which is
paralleled by a decrease in the expression of Myogenin
and MRF4 (differentiation) suggests that the switch be-
tween Notch (proliferation) and Wnt (differentiation)
signaling pathway is dysfunctional leading to a sustained
proliferative state, a finding that is corroborated by a
previous study [40]. Furthermore, the increased number
of central nuclei observed in this group is in line with
the notion that satellite cells are under a sustained pro-
liferative state.
Figure 5 A) Pax7, B) MyoD, C) Myf5, D) Myogenin, E) MRF4 and F) Numb protein accumulation during myogenesis in satellite cells
isolated and cultured from healthy subjects (white bars; n = 7) and patients with COPD (black bars; n = 8). Protein extraction was
performed daily, the first three days represent the myoblasts phase past than is the differentiation phase (day 3 to day 9). Signal analysis was
calculated by densitometry and reported over a positive control. When a is present: statistically significant difference from control
(ANOVA; p < 0.05).
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lateralis
When sufficient muscle tissue was available, we success-
fully isolated and cultured satellite cells from patients with
COPD and healthy subjects. Phenotype was confirmed by
positive staining for both Pax7 and MHC, two specificmarkers only found in muscle cells ensuring the quality of
this model [12,41]. Moreover, isolated cells had myoblast-
like and myotube-like morphologies and expressed spe-
cific MRFs during the proliferation and differentiation
steps. This protocol allows the culture of satellite cells iso-
lated from fresh human biopsies with high purity and
Figure 6 Skeletal myosin fast twitch protein accumulation
during myogenesis in satellite cells isolated and cultured from
healthy subjects (white bars; n = 9) and patients with COPD
(black bars; n = 8). Protein extraction was performed daily after
initial differentiation. Signal analysis was calculated by densitometry
and reported over a positive control. When a is present: statistically
significant difference from control (ANOVA; p < 0.05).
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as proliferation and differentiation. We found that satellite
cells isolated from patients with COPD expressed a de-
layed activation and compromised differentiation when
compared with healthy controls cells.
Interestingly, satellite cell adhesion to culture dish was
delayed in patients with COPD, suggesting an impaired
response to adhesion signals. Cellular proliferation is an
essential event for muscle regeneration because the ex-
pansion of myogenic cells is needed to provide a sufficient
number of new myonuclei for tissue repair [42]. Thus, sat-
ellite cell activation must occur within 6 hours post-injury
and be followed by robust proliferation within 48 hours to
induce an effective muscle regeneration [43,44]. Although
unexplained, the delay in satellite cell adhesion observed
in COPD supports the notion that the regenerative
process could be altered in this patient population. To fur-
ther characterize satellite cell activity in the context of
COPD, we specifically compared the rate of proliferation
of cultured cells isolated from muscle specimens and
found that once activated, satellite cells from patients with
COPD were able to compensate for their initial delay and
produce even more myoblasts after 96 hours in culture
than controls.
The proliferation of satellite cells in the context of
COPD followed a distinct pattern compared to healthy
subjects. Excessive oxidative stress is able to induce a
delay in myoblast proliferation [45] and extensive in-
flammatory response alters differentiation. Because oxi-
dative stress and low grade of systemic inflammation
have been reported in COPD [46-48], this ambient mi-
lieu could promote dysfunctional proliferation pattern ofsatellite cells in COPD. Our conditions for cell culture
were optimal and withdrawal of inflammatory and/or
oxidative stress stigmas might explain the recrudescence
in the proliferation rate seen after a few days in the cul-
ture dish.
Expression of myogenic regulatory factors during
myogenesis
The basic–helix-loop-helix (bHLH) MRFs Myf5, MyoD,
myogenin, and MRF4 act as transcriptional activators of
skeletal muscle genes [49]. Myf5 and MyoD act together
on a genetic pathway upstream of myogenin and MRF4
to program myogenesis in skeletal muscle cells and it
has been suggested that they can counterweigh their
own individual actions. For instance, mice lacking func-
tional MyoD gene were found to express about four-fold
higher levels of Myf5 leaving them without abnormalities
in skeletal muscle development [50]. In our study, dur-
ing the process of differentiation of satellite cells, we
found a three-fold increase in Myf5 content in COPD
even if MyoD accumulation was similar between both
groups. This observation suggests that MyoD activity
might be compromised in satellite cells growing in a dis-
tinct environment such as in COPD. Because Myf5 alone
is able to support the appropriate progression of myo-
genesis as demonstrated by the similar expression of
myogenin and MRF4 in both groups in the differenti-
ation phase, we believe that in optimal culture condi-
tions, satellite cells isolated from patients with COPD
are able to coordinate their progression toward the for-
mation of myoblasts.
However, the last step of differentiation appears to be
affected in COPD. Indeed, the reduced MHC protein ac-
cumulation observed in satellite cells from patients with
COPD is a strong evidence of an altered differentiation
capacity. It can be speculated that the inability of myo-
blasts to fuse together, a prerequisite step to engage the
late MRFs into their transcriptional activity, could ex-
plain this finding [51,52]. Altered transitional signaling
in the Notch/Wnt balance is a likely explanation for this
observation. The novel finding that impaired Notch sig-
naling may be partly responsible for the loss of myogenic
potential in aged muscle is intriguing, and provides a po-
tential clue into the mechanisms underlying this altered
regenerative process [34,53]. Because this study was
not designed to specifically address the function of
these membrane proteins, further experimentations are
warranted to better characterize their role in the regen-
erative activity of satellite cells isolated from patients
with COPD.
Limitations of the study
Because of the nature of the study design, it is difficult
to determine causality between impaired regenerative
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small number of muscle specimens were used for cell
isolation and culture. As a consequence, it was not pos-
sible to test the impact of muscle atrophy on satellite
cell behaviour when placed into culture. In a similar
way, the study was not designed to pursue mechanistic
investigations. Even if these limitations are present, this
innovative study brings some exciting results that pro-
vide foundation for further experimentations aimed at
understanding the impact of impaired muscle regener-
ation on the atrophying process observed in COPD and
other chronic conditions.
Conclusion
We provide strong evidence of a defect in satellite cells
biology in the vastus lateralis muscle of patients with
COPD. Because cultured satellite cells isolated from
muscle samples obtained in patients with COPD have
atypical expression pattern of MRFs that may result in
poor MHC accumulation in myotubes compared to
healthy subjects, we believe that muscle tissue regener-
ation could be impaired in COPD. The relevance of this
finding for the development of muscle atrophy in this
disease will need to be considered in future studies. Fur-
ther efforts to delineate how the in vivo environment
(growth factor availability, nature and intensity of the
stressors) can affect the intrinsic capacity of satellite cells
to regenerate muscle tissue will be useful.
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